Adaptive Biotechnologies Reports 55% Revenue Growth and Sharp Rise in clonoSEQ Testing Volume for 2025
Preliminary Results Show Strong Acceleration in MRD Business
Adaptive Biotechnologies (NASDAQ: ADPT) delivered a notable update ahead of its formal earnings release, revealing robust momentum for both the fourth quarter and full year 2025. The company’s preliminary and unaudited figures show that total revenue reached approximately $277 million for the year, a 55% increase compared to 2024. Minimal Residual Disease (MRD) revenue also saw a significant jump, up 46% for the year.
clonoSEQ Test Volume Grows 39%—Indicating Strong Market Uptake
One of the standout metrics in the report was the expansion in clonoSEQ test adoption. Test volume for the year reached approximately 105,600, representing a 39% increase from the prior year. The uptake was particularly notable in the fourth quarter, with test volume up 43% to around 30,000 tests compared to the same period in 2024.
| Metric | Q4 2025 | Full Year 2025 | Change vs 2024 |
|---|---|---|---|
| Total Revenue | $72M | $277M | +55% |
| MRD Revenue | $62M | $212M | +46% |
| clonoSEQ Volume | 30,000 | 105,600 | +39% |
| Cash, Equiv. & Marketable Sec. | — | $227M | — |
Financial Position Remains Strong Heading Into 2026
The company ended the year with approximately $227 million in cash, cash equivalents, and marketable securities, providing flexibility for continued growth and investment. Management indicated that the net loss for the fourth quarter and full year 2025 is expected to decrease compared to 2024, though precise figures will be announced in February 2026.
Company Outlook: Focused on Sustaining Momentum in MRD
CEO Chad Robins emphasized that 2025 was pivotal for Adaptive, citing the ‘accelerating momentum across our MRD business driven by strong growth in clonoSEQ adoption.’ Looking ahead, the company aims to further its leadership in MRD testing, sustain strong volume and average selling price growth, and expand MRD profitability.
Takeaway: Key Metrics Point to Building Strength in Core Business
Adaptive’s preliminary 2025 figures paint a picture of accelerating top-line growth and strong adoption of its clonoSEQ MRD test. While financials are unaudited and subject to change, the 55% surge in revenue and increased test volume suggest strong operational execution. Investors will want to watch the official results in February to get a deeper view, especially regarding expense trends and the pathway to profitability in 2026.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI